Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | BRAF | P15056 | 5/20 | 0.46 |
| ▸ | KDR | P35968 | 2/20 | 0.46 |
| ▸ | IDH1 | O75874 | 14/20 | 0.44 |
| ▸ | RAF1 | P04049 | 1/20 | 0.42 |
| ▸ | NPC1 | O15118 | 1/20 | 0.41 |
| ▸ | RAB9A | P51151 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5363478 | 0.89 | BRAF (0.45) | BRAFKDRIDH1RAF1NPC1 | |
| SCHEMBL1754894 | 0.87 | BRAF (0.44) | BRAFKDRIDH1RAF1 | |
| SCHEMBL1754862 | 0.87 | BRAF (0.46) | BRAFKDRIDH1RAF1 | |
| SCHEMBL4556886 | 0.83 | BRAF (0.43) | BRAFKDRIDH1RAF1 | |
| SCHEMBL5359860 | 0.76 | BRAF (0.44) | BRAFKDRIDH1NPC1RAB9A | |
| SCHEMBL12413879 | 0.76 | PTGES (0.46) | BRAFKDRRAF1 | |
| SCHEMBL12413884 | 0.75 | PTGES (0.42) | BRAFKDRRAF1 | |
| SCHEMBL5365202 | 0.75 | BRAF (0.53) | BRAFKDRIDH1NPC1RAB9A | |
| SCHEMBL4556565 | 0.74 | BRAF (0.57) | BRAFKDRIDH1NPC1RAB9A | |
| SCHEMBL12413902 | 0.71 | PTGES (0.42) | BRAFNPC1RAB9A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7301036-B2 | Cyclic guanidines, compositions containing such compounds and methods of use | MERCK & CO., INC. (US) | 2007-11-27 | — | — | US | disclosed |
| US-20070105930-A1 | Cyclic guanidines, compositions containing such compounds and methods of use | MERCK SHARP & DOHME LLC | 2007-05-10 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070105930-A1 | Cyclic guanidines, compositions containing such compounds and methods of use | GCGR, GLP1R, GCG | BRAF 3178/4885KDR 1721/4885IDH1 4079/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.